Testing a new cancer drug versus Erbitux for colorectal cancer
Part of Cancer clinical trials.
This study compares a new drug called HLX05-N with an approved drug called Erbitux (cetuximab) in people with advanced colorectal cancer that has spread. The trial tests whether the new drug works similarly or better than Erbitux.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not received chemotherapy or targeted cancer drugs for advanced colorectal cancer before
- Your colorectal cancer started in the left colon or rectum (not the right colon)
- Your cancer has specific genetic markers (wild-type KRAS and NRAS, no BRAF V600E mutation)
- You are 18–75 years old with a BMI between 18.5–30 and weight between 50–85 kg
- You have not had major surgery in the past 4 weeks and have recovered from any surgery
- You have not been treated with drugs targeting blood vessel growth or EGFR pathways before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This Phase 2 trial tests whether a drug combo (HLX07 + HLX10) with standard chemotherapy (mFOLFOX6), or HLX07 alone, can improve outcomes in people with metastatic colorectal cancer. It aims to check both how well it works and how safe it is, especially for tumors with specific gene “wild-type” results.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This trial tests a new drug combination for people with advanced colorectal cancer that has worsened after first treatment. It aims to see if adding these drugs can shrink tumors or slow the disease.
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
This study tests a new approach for people with a specific type of metastatic colorectal cancer that has stopped responding to initial treatments. It compares reusing a targeted drug combination (irinotecan plus cetuximab) versus a different chemotherapy plus a targeted drug (trifluridine/tipiracil plus bevacizumab) to see which works better for patients whose tumors have a certain genetic profile.
Hear when a new mCRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.